IgA Nephropathy

A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives.

A deep dive into several noteworthy IgAN studies presented during the ERA 2025 Congress.

Discover groundbreaking insights on the VISIONARY trial, IgA nephropathy treatment, and the future of kidney care with expert Vlado Perkovic, MBBS, PhD.

Prespecified analysis of 320 patients in VISIONARY were presented at ERA 2025 Congress.

Richard Lafeyette, MD, discusses his reaction to the phase 3 ORIGIN topline results and what it means for IgAN.

Jonathan Barratt, MD, PhD, offers perspective on how the 100-week data from ERA 25 inform the potential of zigakibart.

New 100-week data reveals zigakibart's significant efficacy and safety in reducing proteinuria for IgA nephropathy.

An overview of the 7 presentations included as late-breaking clinical trials at ERA 2025.

Vera Therapeutics intends to bring the results before the FDA by the end of 2025; they anticipate an approval and commercial launch in 2026.

Brendon Neuen, MBBS, PhD, discusses 3 late breaking clinical trials being presented at ERA 2025.

With the priority review acceptance of the Biologics License Application, the FDA has assigned a PDUFA target action date of November 28, 2025.

Pregnancies occurring during or after initial C3G presentation were at a greater risk of preeclampsia, prematurity, and renal function decline.

Recent research uncovers how lifestyle and environmental factors influence the incidence of IgAN and membranous nephropathy.

Symptoms of immunoglobulin A nephropathy were reduced substantially during the 1-month follow-up period.

The month in review spotlights renal FDA news and novel research about CKD and social determinants of health in kidney care.

Norouzi discusses recent advancements in IgAN therapeutics and looks ahead to a potential first FDA-approved FSGS treatment.

Norouzi reflects on significant advances in glomerular disease from Q1 and looks ahead to what the rest of 2025 may have to offer.

Kraus explains current unmet needs in IgA nephropathy and what sibeprenlimab may offer based on the phase 3 VISIONARY study.

Lafayette reflects on recent therapeutic advances in IgA nephropathy and looks ahead to other renal pipeline developments he’s looking forward to in 2025.

Lafayette describes ongoing unmet needs in IgAN care and how the growing understanding of disease pathogenesis has informed drug development.

Our Q1 recap for nephrology spotlights regulatory updates, new clinical trial data, and advancements in xenotransplant.

The approval indicates Novartis's atrasentan (Vanrafia) for proteinuria reduction in primary IgA nephropathy.

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The Biologics License Application submission for sibeprenlimab is supported by results from the phase 2 ENVISION and phase 3 VISIONARY clinical trials.